- Home
- CABA vs ATNI Comparison
CABA vs ATNI Comparison
Compare CABA & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- ATNI
- Stock Information
- Founded
- CABA 2017
- ATNI 1987
- Country
- CABA United States
- ATNI United States
- Employees
- CABA N/A
- ATNI N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- ATNI Telecommunications Equipment
- Sector
- CABA Health Care
- ATNI Telecommunications
- Exchange
- CABA Nasdaq
- ATNI Nasdaq
- Market Cap
- CABA 260.7M
- ATNI 226.4M
- IPO Year
- CABA 2019
- ATNI 1991
- Fundamental
- Price
- CABA $2.45
- ATNI $15.03
- Analyst Decision
- CABA Strong Buy
- ATNI Strong Buy
- Analyst Count
- CABA 8
- ATNI 1
- Target Price
- CABA $11.63
- ATNI $30.00
- AVG Volume (30 Days)
- CABA 5.1M
- ATNI 33.0K
- Earning Date
- CABA 11-13-2025
- ATNI 10-22-2025
- Dividend Yield
- CABA N/A
- ATNI 7.32%
- EPS Growth
- CABA N/A
- ATNI N/A
- EPS
- CABA N/A
- ATNI N/A
- Revenue
- CABA N/A
- ATNI $719,593,000.00
- Revenue This Year
- CABA N/A
- ATNI $1.60
- Revenue Next Year
- CABA N/A
- ATNI $2.06
- P/E Ratio
- CABA N/A
- ATNI N/A
- Revenue Growth
- CABA N/A
- ATNI N/A
- 52 Week Low
- CABA $0.99
- ATNI $13.76
- 52 Week High
- CABA $5.46
- ATNI $32.44
- Technical
- Relative Strength Index (RSI)
- CABA 50.01
- ATNI 49.47
- Support Level
- CABA $2.77
- ATNI $14.26
- Resistance Level
- CABA $3.01
- ATNI $15.24
- Average True Range (ATR)
- CABA 0.37
- ATNI 0.64
- MACD
- CABA -0.03
- ATNI 0.08
- Stochastic Oscillator
- CABA 19.36
- ATNI 78.19
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.